Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arie Regev

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
Diabetes, Obesity & Metabolism|April 4, 2017
Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetesCristina B Guzman, Xiaotian M Zhang, Rong Liu, et al.
Journal of Pediatric Gastroenterology and Nutrition|July 5, 2006
Does the heterozygous state of alpha-1 antitrypsin deficiency have a role in chronic liver diseases? Interim results of a large case-control studyArie Regev, Constanza Guaqueta, Enrique G Molina, et al.
Clinical Transplantation|April 12, 2007
Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infectionHideo Yoshida, Tomoaki Kato, David M Levi, et al.
The American Journal of Gastroenterology|August 23, 2002
Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver diseaseGuy W Neff, Christopher B O'Brien, K Rajender Reddy, et al.
Journal of Hepatology|September 20, 2005
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensationScott K Fung, Pietro Andreone, Steve H Han, et al.
Alimentary Pharmacology & Therapeutics|November 26, 2019
Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver diseaseMelissa Palmer, Arie Regev, Keith Lindor, et al.
Journal of Viral Hepatitis|December 13, 2019
Liver safety assessment in clinical trials of new agents for chronic hepatitis BRobert J Fontana, Mark I Avigan, Harry L A Janssen, et al.
British Journal of Clinical Pharmacology|September 3, 2017
Dose-dependent acute liver injury with hypersensitivity features in humans due to a novel microsomal prostaglandin E synthase 1 inhibitorYan Jin, Arie Regev, Jeanelle Kam, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|September 18, 2004
Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantationArie Regev, Enrique Molina, Rosana Moura, et al.
Transplantation|April 29, 2004
Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantationAndreas G Tzakis, Panagiotis Tryphonopoulos, Tomoaki Kato, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
Diabetes, Obesity & Metabolism|April 4, 2017
Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetesCristina B Guzman, Xiaotian M Zhang, Rong Liu, et al.
Journal of Pediatric Gastroenterology and Nutrition|July 5, 2006
Does the heterozygous state of alpha-1 antitrypsin deficiency have a role in chronic liver diseases? Interim results of a large case-control studyArie Regev, Constanza Guaqueta, Enrique G Molina, et al.
Clinical Transplantation|April 12, 2007
Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infectionHideo Yoshida, Tomoaki Kato, David M Levi, et al.
The American Journal of Gastroenterology|August 23, 2002
Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver diseaseGuy W Neff, Christopher B O'Brien, K Rajender Reddy, et al.
Journal of Hepatology|September 20, 2005
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensationScott K Fung, Pietro Andreone, Steve H Han, et al.
Alimentary Pharmacology & Therapeutics|November 26, 2019
Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver diseaseMelissa Palmer, Arie Regev, Keith Lindor, et al.
Journal of Viral Hepatitis|December 13, 2019
Liver safety assessment in clinical trials of new agents for chronic hepatitis BRobert J Fontana, Mark I Avigan, Harry L A Janssen, et al.
British Journal of Clinical Pharmacology|September 3, 2017
Dose-dependent acute liver injury with hypersensitivity features in humans due to a novel microsomal prostaglandin E synthase 1 inhibitorYan Jin, Arie Regev, Jeanelle Kam, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|September 18, 2004
Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantationArie Regev, Enrique Molina, Rosana Moura, et al.
Transplantation|April 29, 2004
Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantationAndreas G Tzakis, Panagiotis Tryphonopoulos, Tomoaki Kato, et al.
Pageof 7